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Sulnn'lary 
The initial, phase of membrane attack by complement is the interaction between C5b6,  C7, 
and the cell membrane that leads  to the insertion of C5b-7.  Here we investigate the role of 
sialic acid residues in the assembly of C5b-7 intermediates on erythrocyte cell membranes. We 
find that C5b6 binds to glycophorin, whereas C5 or C6 does not bind, and desialylation of the 
glycophorin abolishes C5b6 binding.  Complement lysis is inhibited by either masking glyco- 
phorin sialic acid with F~b fragments of an mAb, or by removal of the sialylated region of glyco- 
phorin by mild trypsinization. Gangliosides inhibit C5b-7 deposition when added to the aque- 
ous  phase.  Asialogangliosides  and  synthetic  gangliosides  lacking  the  carboxylic acid  residue 
have no inhibitory activity. We conclude that C5b6 binds to sialylated molecules on the eryth- 
rocyte surface. We propose a new model of membrane attack in which C5b6 initially binds to 
membranes via ionic forces. C7 then binds to C5b6, disrupting the ionic interaction and lead- 
ing to the exposure of hydrophobic domains. Sialic acid is known to inhibit complement acti- 
vation. Thus, these findings reveal a paradoxical role for sialic acid in complement attack; the 
presence of sialic acid inhibits the generation of C5b6, but once the membrane attack pathway 
is initiated, sialic acid enhances complement lysis. 
T 
he membrane attack complex of the complement sys- 
tem consists  of five proteins, C5, C6, C7, C8, and C9 
(1-3).  On  activation,  these  proteins  expose hydrophobic 
residues, insert into membranes, and form trans-membrane 
channels  (2,  3).  The process of channel formation can be 
divided into two phases:  the initial interaction between the 
cell membrane,  C5b6,  and  C7  to  form  a  stably  inserted 
C5b-7  complex,  and  the  subsequent  addition  of C8  and 
multiple C9  molecules to form a trans-membrane  channel 
(4, 5). The initial association of C5b-7 with the membrane 
is  of central  importance  because  it  commits  the  C5b-9 
complex to a particular site on the membrane at which the 
C5b-9 complex will assemble. We have previously shown 
that when erythrocytes are treated with C5b-9,  the com- 
position of the membrane that is shed as the cell vesiculates 
differs from the composition of the bulk plasma membrane, 
implying that  the  channels  localize to  certain  membrane 
domains (reference 6 and Marshall, P.M., and M.B. Whitlow, 
unpublished observations). In addition, if the C5b-7 com- 
plex does not associate  productively with the membrane, it 
can serve as an inhibitor of C5b-9 formation by binding to 
vitronectin and SP 40-40 to bind irreversibly C8  and C9, 
making them unavailable for channel formation (7, 8). De- 
spite the important role of the membrane insertion of C5b-7, 
the precise mechanisms involved in this interaction are un- 
known. The current view is that after proteolytic activation 
of C5, the C5b fragment binds to C6. The C5b6 complex 
remains loosely bound to the cell surface, but the specific 
membrane  molecules  have  not  been  identified  (9,  10). 
Some evidence indicates that C5b6 may remain associated 
with the C3b subunit of the C5 convertase (9,  11).  Other 
findings have suggested that ionic forces play an important 
role in  C5b6  binding  and  C5b-7  deposition.  Silversmith 
and Nelsestuen showed that binding of C5b6 to lipid vesi- 
cles  is  dependent  on  lipid  composition;  C5b6  bound  to 
vesicles composed of either phosphatidic acid or phosphati- 
dylglycerol, but did not bind to vesicles composed ofphos- 
phatidylcholine,  phosphatidylserine,  or phosphatidylinosi- 
tol  (12).  In  addition,  polyanions such as heparin decrease 
membrane deposition of C5b-7  (13,  14).  At physiological 
pH eukaryotic cells are negatively charged, thus the inhibi- 
tory activity  of polyanions  may  represent  a  competition 
with the cell surface for binding (15). 
Although  these  observations highlight the  participation 
of anionic surface molecules in the assembly of C5b-7, the 
structure of these surface molecules has  not been defined. 
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and  gangliosides  are  the  major  polyanions  of erythrocyte 
membranes.  The  present  investigation is aimed at defining 
the  role  of these  sialic acid  moieties  in  C5b67  membrane 
assembly. 
Materials  and Methods 
Buffers and Solutions.  All buffers were prepared with glass-dis- 
tilled  water  and  ultraflltered  before  use.  PBS  was  composed  of 
150 mM NaC1, 5 mM sodium phosphate,  pH 7.4.  DGVB  2+ was 
composed  of veronal-buffered  saline  containing  71  mM  NaC1, 
139 mM dextrose, 2.5 mM sodium veronal, (pH 7.4), 0.1% gela- 
tin, 0.15 mM CaC12, and  1 mM MgC12.  GVB  2+ veronal buffered 
saline  containing  142  mM  NaC1,  2.5  mM sodium  veronal  (pH 
7.4), 0.1% gelatin, 0.15 mM CaC12, and 1 nfiVl MgC12. 
Sialic Acid Determination.  Erythrocytes  were  lysed  and  the 
membranes washed five times in 5 mM sodium phosphate buffer, 
pH 7.8.  The membrane pellet was resuspended  in an equal vol- 
ume of phosphate buffer, followed by an equal volume of 0.2 M 
H2SO 4  (0.1  M  final concentration).  The  membranes  were  then 
hydrolyzed at 80~  for 60 rain and the free sialic acid released as- 
sayed by an adaptation of the thiobarbituric acid method (16). 
Erythrocytes and Complement  Components.  Guinea pig erythro- 
cytes were stored in Alsever's solution until use, and washed three 
times with veronal-buffered saline containing 142  mM NaC1 and 
5 nflVl sodium veronal, pH 7.4.  Human erythrocytes were collected 
by venipuncture  from volunteers.  Blood was  initially collected 
in  buffered  EDTA  solution,  washed,  and  stored  in  DGVB  2+. 
Throughout  this  study,  only  human  complement  components 
were used.  C5b6  was prepared  from plasma  according to Yama- 
moto and  Gewurz  (17)  with minor modifications (18).  C7,  C8, 
and C9 were purchased from Quidel (San Diego, CA). 
hworporation of Gamfliosides into Erythrocytes.  For these  experi- 
ments ganglioside GTIb (Sigma Chemical Co., St. Louis, MO), at 
two  concentrations,  7.6  Dg/ml  and  3.8  Izg/ml,  was  incubated 
with  guinea  pig erythrocytes  (8.7  ￿  10S/ml)  for  2  h  at  37~ 
Cells  were  then  washed  three  times  in  PBS  containing  0.25% 
BSA. An aliquot of cells was then further washed and analyzed for 
sialic acid. To calculated ganglioside incorporation, we measured 
sialic acid,  which is 37.9%  by weight of ganglioside GTlb.  Cells 
were then used in hemolytic assays. 
Hemolytic Assays.  Hemolytic  assays were  performed  as  in 
(18).  Briefly,  0.1  ml  of 1.5  X  10  s  erythrocytes  were  incubated 
with various dilutions of C5b6 at 30~  for 30 min. C7 was then 
added  and  the  mixture  incubated  at  30~  for an  additional  15 
rain. C8 and C9 were then added and the cells incubated at 37~ 
for 60 min.  Cells were then pelleted and hemolysis estimated by 
the  absorbance  of hemoglobin  at  412  nm.  In  experiments  in 
which  gangliosides  were  added  as  complement  inhibitors,  the 
molecules of interest were added immediately before C5b6 addi- 
tion.  In  several  experiments  gangliosides  or  glycophorin  were 
added  with  C8  and  C9.  In  these  experiments,  the  cells  were 
washed after the incubation with C5b6  and  C7.  Cells were then 
resuspended,  the inhibitor added, C8 and C9 added, and the cells 
incubated at 37~  for 60  rain.  C5  assays were carried out using 
GPE ~ and C5-deficient human serum (CSDS) (Quidel). 0.1  cc of 
~  Abbreviations used in this paper: CNBr-Sepharose,  cyanogen bromide-acti- 
vated  Sepharose;  GPE,  guinea  pig erythrocytes;  ICs~,, concentration  of 
ganglioside that inhibited lysis by 50%; SCR, short consensus repeat; TS1, 
thrombospondin  type 1. 
guinea  pig erythrocytes  (GPE)  (1.5  +  10U/ml)  in  GVB  2+  were 
incubated  with  0.2  ml  C5DS  supplemented  with  4  I~g  Clq 
(Quidel). 0.1  ml of the column fractions was added,  and the cells 
incubated  at  37~  for 60  min and  hemolysis measured  spectro- 
photometrically.  C6  was  assayed  in a  similar manner  using C6- 
deficient serum (Quidel). 
Treatment of Human Erythrocytes with Trypsin.  Human  erythro- 
cytes (2.5  ml, 2  ￿  109/111]) were incubated with  100  ILl of L-(to- 
sylamido  2-phenyl)ethyl  chloromethyl  ketone-treated  TPCK- 
trypsin (Sigma) in 50 mM sodium phosphate,  pH 7.5, at 37~  fbr 
45 min. The reaction was stopped by the addition of 750 ~g soy- 
bean  trypsin  inhibitor  (Sigma)  and.allowed  to incubate  at  room 
temperature for 5 rain.  Cells were washed four times in PBS and 
stored in DGVB  2+. To assess the degree ofglycophorin cleavage, 
the cell membranes were run  on SDS PAGE, and Western blot- 
ting was performed  using monoclonal antiglycophorin  antibody 
(Sigma). This antibody binds to glycophorins A and B.  Cleavage 
of glycophorin was estimated by the disappearance  of the glyco- 
phorin A  dimer at 85 kD.  The degree of cleavage was estimated 
visually. 
Glycophotin-Sepharose  and  Asialoglycophoritl-Sepharose  Columns. 
Cyanogen  bromide-activated  Sepharose  (CNBr-Sepharose)  was 
purchased from Pharmacia Biotech Inc. (Piscataway, NJ), and was 
used according to the manufacturer's instructions. Briefly, tim gel 
was washed with 1 mlVl HCI, pH 3.0. Human glycophofin (Sigma) 
was resuspended in coupling buffer ((I.1 M  NaHCO.~, 0.5 M  NaCI, 
pH 8.36)  and added to the activated CNBr-Sepharose with mix- 
ing overnight at 4~  7  mg glycophorin was  coupled  to  7.0  ml 
CNBr-Sepharose. Coupling efficiency was 83%. The cohmm was 
then blocked with 0.1 M  Tris, pH 8.0,  for 4 h at room tempera- 
ture. Beads were washed in PBS. An affinity column  (3.1) X  1.5 
cm)  was  prepared,  and  the  column  was  stored  at  4~  in  PBS- 
azide until use.  To desialylate the glycophorin, the glycophorin- 
sepharose  column  was  loaded  with  Vibrio choleric sialidase.  1  U 
sialidase  in  2.5  nil  was  added  to  the  column  and  incubated  at 
room temperature for 60 rain. The eluate was monitored for frec 
sialic acid, and  100% of the sialic  acid was released by this proce- 
dure. For the affinity column experiments, 37 b~g of C5, 37 ~g of 
C6, or 37 btg of C5b6 was dialyzed against  10 mM sodium phos- 
phate,  pH  7.5.  The  complement  component  of  interest  was 
loaded onto the colunm,  and the column washed with two col- 
umn volumes of 10 mM sodium phosphate,  pH 7.5.  Bound ma- 
terial was  eluted  with  two-column  volume gradient  to  10  mM 
sodium phosphate/100  mM NaC1, pH 7.4.  Fractions were tested 
for hemolytic activity and conductivity measured at 22~ 
Generation  and  Use  0f F,,I, Fragnlents qf Antiglycophorin  Antibod- 
ies.  Monclonal antiglycophorin antibodies 3H2 and 2B10 were 
generated as in reference  19.  Both are mouse IgGL, K. The anti- 
body was purified from ascites using an anti-nmuse  IgGragarose 
colunm  (Sigma).  F d  , fragments were produced by the method of 
Mishell  and  Shiigi  (18a).  Briefly,  antibody  was  dialyzed against 
0.1  M  phosphate  4  ￿  10 -3 M  EDTA,  pH  7.0.  The  antibodies 
were incubated with mercuripapain  (Sigma) (2% wt/wt),  ll) --~ M 
cysteine,  4  ￿  10 -3  M  EDTA,  for  4  h  at  37~  Reaction  was 
stopped  by addition  of 50  b~l of 0.3  M  iodoacetamide,  pH  8.0. 
The mixture was held on ice for 30 rain and dialyzed against  0.1  M 
Tris,  pH  8.  F~,  b fragments  were  purified  by absorption  of undi- 
gested antibodies and F~. fragments to proteins  G  beads  (Pharma- 
cia),  and  purity  of the  Fat  ,  fragments  confirmed by  SDS-PAGE. 
For the experiments using the F.~  b,  100  Ftl of human  mTthrocytes 
(1.5  ￿  109/1111) was incubated with various dilutions of F:,, frag- 
ments  for 30  rain  at 37~  Cells were  washed  twice i,  GVt3  e+ 
and used in a hemolytic assay. 
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Figure 1.  C5b6 binds to glycophorin-Sepharose but not to asialoglyco- 
phorin-Sepharose. (A) C5, C6, or C5b6 was loaded onto a glycophorin- 
Sepharose column in 10 mM sodium phosphate, pH 7.5. After washing, 
the column was eluted with a gradient from 0 to 0.1 M  NaC1 in 10 m/Vl 
sodium phosphate, pH 7.5.  Shown are C5  ([3),  C6  (A), C5b6  (￿9  and 
conductance (O).  (B) Experiments were conducted on the same column 
as A, before and after neuraminidase treatment. C5b6 was loaded onto the 
column, and the chromatography performed as outlined in A. The elu- 
tion profiles from asialoglycophorin ([7),  glycophorin (￿9  and conduc- 
tance (O) are shown. 
Gangliosides.  (R  =  -CH2CH(NH-CO-CI7H3s)-CHOH-CH= 
CH-C13H27  ,  Cer,  ceramide);  asialo GM  b  galactose-ceramide 
(GalCer); GM  l, GM2, GDib, and GTib were purchased fi'om Sigma. 
Monosialoganglioside  GM3, Neu5Ac(c12-3)DGal(131-4)  DGlc- 
O-R~, GSC-17 (20); Neu5Ac(0~2-6)DGal(131-4)DGlc-O-R1,  GSC- 
61  (21); 7-deoxy GM3, GSC76  (22); 4-methoxy GM3, GSC78 
(23);  8-deoxy  GM3, GSC153  (24); Neu5Ac(o~2-3)DGal-Cer, 
GSC26  (25); NeuS(OH)(oL2-3)DGal(131-4)DGlc-Cer,  GSC198 
(26);  Neu5(OH)(o~2-3)DGal-Cer,  GSCl13  (27); O-95-aceta- 
mido-3,5-dideoxy-D-glycero-Cl-D-galacto-2-nonulopyranosyl)-(2-3)- 
O-13-D-glyucopyranosyl-  (1-1)- (2S,3R,4E)-2-octadecanamido-4- 
octadecene-l,3-diol, GSC80  (28). 
Results 
Affinity  Chromatography  on Gluycophorin-Sepharose  and Asia- 
loglycophorin-Sepharose.  To demonstrate binding to glyco- 
phorin,  C5, C6, or C5b6 was chromatographed on glyco- 
phorin-agarose. Fig.  1A shows that C5b6 is retained, while 
C5  or  C6  alone  is  eluted  in  the  breakthrough.  Fig.  1  B 
Human Glycophorin 
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Figure 2.  Structure of glycophorin. The O-glycosidically linked tetra- 
sacchafides (A)  and the asparagine-linked oligosaccharide  (O)  are indi- 
cated. T2, fragment released by trypsin; membrane-spanning domain. 
shows  that  C5b6  binding  requires  sialylated  glycophorin, 
since treatment with sialidase abolishes the interaction. 
Effect  of Antiglycophorin  mAbs  on  C5b-9-mediated  Lysis. 
To assess the functional consequences  of C5b6 binding to 
membrane  glycophorin,  we  performed  blocking  experi- 
ments  using  Fab  fragments  of the  monoclonal  antiglyco- 
phorin  antibodies,  2B10  and  3H2.  Fig.  2  is  a  diagram of 
human glycophorin. It consists of 131  amino acids in three 
domains: an extracellular domain (amino acids 1-72), a trans- 
membrane domain (amino acids  73-91),  and an intracellu- 
lar  domain  (amino  acids  92-131).  Glycophorin is  readily 
cleaved by trypsin on the COOH-terminal side of the argi- 
nine residue at amino acid 31  to release the T2 fragment. 
T2 contains  11  of the  15  O-glycosidically linked tetrasac- 
charides  (each tetrasaccharide contains two sialic  acid resi- 
dues),  mAB  2B10  binds  to sialic  acid  residues  on the  T2 
fragment and 3H2 binds in  close proximity to  the  mem- 
brane (amino acids 55-70)  (19).  On the basis of our bind- 
ing data, we reasoned that 2B10, but not 3H2, might block 
0"25  'F  /11,,. 
//  "!= ~  ~  ~  ~  t  31-12 
iii 
021  "'  i  i  i 
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Fab added  (l.tg  protein) 
Figure 3.  Complement-mediated lysis of erythrocytes treated with an- 
tiglycophorin mAb. Human erythrocytes were pretreated  with Fab frag- 
ments of 2B10 (O) and 3H2 (m). Cells were washed, C5h-9 added, and 
hemolysis assessed. 
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Figure 4.  Treatment of human erythrocytes with trypsin decreases sus- 
ceptibility to reactive lysis. Human erythrocytes were trypsinized, washed, 
and treated with C5b-9. 
the binding  of C5b6  to red  cells. As can be seen in Fig.  3, 
Fab fragments of 2B10 inhibit lysis, while the Fab fragments 
of 3H2  do  not.  FACS |  analysis  (not shown)  demonstrates 
binding of both Fab fragments to the erythrocyte. 
Effect of Trypsin  Treatment on Lysis.  To confirm the data 
obtained with mAbs, we subjected human erythrocyte gly- 
cophorin  to  trypsin  digestion  to  release  the  T2  fragment 
(19,  29).  After trypsin treatment,  samples of red cell mem- 
branes were  run  on  SDS  PAGE  and  glycophorin  cleavage 
was  assayed by Western  blot  using monoclonal  antiglyco- 
phorin  antibody.  5  b~g/ml  trypsin  cleaved  ,--~50% of the 
glycophorin, and 50  b~g/ml trypsin cleaved 80% of the gly- 
cophorin  (not  shown).  Fig.  4  shows  the  relationship  be- 
tween the concentration of trypsin used to treat the erythro- 
cytes and subsequent lysis in a hemolytic assay. Cleavage of 
the  glycophorin  is associated with  a  significant  decrease  in 
lyric susceptibility.  Taken  together with  the mAb-blocking 
experiments, we conclude that the sialylated portion ofgly- 
cophorin  acts as a productive  acceptor for C5h6,  i.e.,  it in- 
creases the  efficiency of channel  formation by the terminal 
complement components. 
Effect of Exogenous  Gangliosides on Lysis.  The major sources 
of erythrocyte  sialic  acid are glycophorin  and  gangliosides. 
To determine whether gangliosides can also act as acceptors 
for C5b6,  we performed competition experiments,  in which 
gangliosides  were  present  during  the  incubation  of C5b6 
and  C7  with  the  erythrocytes.  These  experiments  were 
performed  with  guinea  pig  erythrocytes,  as  they  contain 
gangliosides  and  demonstrate  greater  sensitivity  to  human 
C5b-9.  Fig. 5  shows that sialylated gangliosides inhibit lysis 
significantly,  while  the  asialo  GM1  does  not.  The  disialo- 
ganglioside  (GDlb) shows greater inhibition  than the mono- 
sialogangliosides,  consistent  with  the  hypothesis  that C5b6 
interacts  with  the  sialic  acid  residues.  When  gangliosides 
were  present  only during  incubation  of cells with  C8  and 
C9,  there was an effect on lysis (not shown). 
Figure 5.  Inhibition of hemolysis by exogenous gangliosides. Ganglio- 
sides were incubated with  GPE and human C5b-7.  Cells were washed, 
C8 and C9 added, and hemolysis  measured after 60 min. 
Effect of Ganglioside Incorporation on Lysis.  The data shown 
in  Fig.  5  relate  to  the  inhibition  of lysis  by  gangliosides 
added  to  the fluid phase.  The  assess  the  role of membrane 
gangliosides, we incorporated  the trisialoganglioside,  GTlb, 
into  erythrocytes  and determined  their susceptibility  to ly- 
sis.  To  quantitate  levels  of ganglioside  incorporation,  we 
measured  the  increase  in  sialic  acid  in  the  membrane.  As 
can be seen in Fig.  6, the presence of the trisialoganglioside 
results in  a  significant  increase  in lysis by C5b-9.  We per- 
formed similar experiments with the monosialogangliosides 
GM1  and  GM3,  but  there  was  no  measurable  uptake  of 
ganglioside  or change  in hemolysis  of the  treated  erythro- 
cytes. 
Role of Free Sialic Acid on Reactive Lysis.  Fig.  7  shows that 
GM  3 effectively inhibits  C5b-9-mediated  hemolysis, whereas 
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Figure 6.  Membrane-incorporated trisialogangliosides increase CSb-Q- 
mediated lysis. Guinea pig erythrocytes were incubated with ganglioside 
GTu,, washed, and treated with C5b-9. GT~b  incorporation was estimated 
by measurement of membrane sialic acid. 
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Figure 7.  Inhibition of C5b-9-mediated  lysis by sialic acid, sialyl-lac- 
tose, and GM 3. Sialic acid (Q), sialyl-lactose (A), or ganglioside GM  3 (m) 
were incubated with GPE and human C5b-7. Cells were washed, C8 and 
C9 added, and hemolysis measured after 60 rain. 
free sialic acid and sialyl-lactose do not. Therefore the sialic 
acid must be part of a larger molecule,  or must be multiva- 
lent to inhibit C5b-7 deposition on the membrane. 
Structure-Function Mapping of Ganglioside GMj.  We  next 
used competition  experiments  to study the  effect of struc- 
tural  changes  in  the  sialic  (neuraminic)  acid  residue  of 
GM  3  on  the  interaction  with  C5b67.  Native  GM  3  is 
Neu5Ac(ot2-3)Gal(J31-4)Glc-Cer  (GSC17).  Inhibitory  ac- 
tivity of native GM  3 and some synthetic GM  3 analogues are 
shown  in  Fig.  8.  GSC80  has  an  alcohol  substituted  for a 
carboxylic  acid  on  the  1  carbon  of sialic  acid,  and  has no 
inhibitory  activity.  GSC23  lacks  the  exocyclic  side  chain 
(consisting of carbons 8 and 9) and shows diminished activ- 
ity.  The  analogue  GSC198,  which  substitutes  a  hydroxyl 
for  the  N-acetyl  group  on  carbon  5  of sialic  acid,  also 
shows reduced  activity.  The absence of carbon 9  (GSC23) 
has no significant effect. In data not shown,  removal of the 
glucose  residue  from  GM  3  (Neu5Ac[a2-3]Gal-Cer)  in- 
creased  the  ICs0 from  1  p~g to  7  Izg.  Thus,  structural  fea- 
tures  in  addition  to  carboxylic  acid  are  involved  in  C566 
recognition.  Other modifications without  significant effect 
are: lack of a hydroxyl moiety on carbon 4,  carbon 7,  car- 
bon  8,  or carbon  9;  methylation  of the  4-OH  group;  and 
changing  the  linkage  between  the  sialic  and  galactose  to 
([32-1). 
Discussion 
Membrane  deposition  of  the  C5b-7  complex  is  en- 
hanced by the presence  of the  two  sialylated molecules  of 
the  erythrocyte  membrane,  gangliosides  and  glycophorin. 
In  this  work  we  demonstrate  direct  binding  of C566  to 
glycophorin,  and  show  that  this  binding  is  dependent  on 
the presence of sialic acid.  The net effect of C5b6 binding 
to glycophorin  in  the membrane is to increase  C5b-7  up- 
take  as determined  by mAb studies  and  trypsinization  ex- 
periments.  Gangliosides, the other major source oferythro- 
cyte  sialic  acid,  also  enhance  the  efficiency  of  C5b-7 
deposition.  Gangliosides added  to the fluid phase compete 
with the erythrocyte membrane for C5b67 uptake, and this 
inhibition is dependent on ganglioside sialic acid. The inhi- 
bition  of lysis by sialic  acid requires  that the  sialic  acid be 
part of a macromolecule such as glycophorin or a ganglio- 
side;  free sialic  acid  or sialyl-lactose has no  activity.  Using 
synthetic ganglioside  analogues,  we demonstrate  the struc- 
tural  features  important  for  the  interaction  with  C5b-7. 
The  carboxylic acid residue is essential for the interaction, 
and modification ofsialic acid, either by the removal of the 
exocyclic  side  chain,  or  by  the  removal  of the  N-acetyl 
group,  also decreases the effectiveness of ganglioside-com- 
plement interaction. 
A  number of membrane proteins have been shown to be 
inhibitors  of complement  activation.  The  studies  reported 
here  show  that membrane  molecules,  specifically ganglio- 
sides  and  glycophorin,  can  serve  to  enhance  complement 
attack.  These  studies  highlight  a  paradox,  since  sialylated 
membrane  molecules  inhibit  human  complement  activa- 
tion.  Sialic acid enhances  the  affinity of factor H  for C3b. 
This binding has two important consequences:  (a) factor B 
Name  Variations  in Neu5Ac 
GSC80  1-hydroxy NeuSAc 
GSC23  (C7)Neu5Ac 
GSC198  5-hydroxy  Neu 
GSC24  (C8)Neu5Ac 
GSC17  Neu5Ac 
'  FI  r"lr  ti liil  I  lltli  t,I  tl 
! 
| 
r  I  i  i 
5  10  15  20 
IC~ ~g/ml 
> 25 ~g/ml 
25 
Figure 8.  Inhibition of lysis by exogenous synthetic 
GM 3  analogue. Various synthetic analogues of GM  3 
were titrated with  GPE and C5b-7,  washed, and C8 
and C9 added. 
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alternative pathway C3 convertase; and (b) factor H  acts as 
a cofactor to promote the cleavage and inactivation of C3b 
by  factor  I  in  both  the  classic  and  alternative  pathways. 
Thus the presence of sialylated membrane molecules inhib- 
its both pathways of complement activation, although  the 
effect on the alternative pathway is more significant (30).  If 
the complement system is able to overcome this inhibition, 
the presence of sialic acid on adjacent membrane molecules 
enhances  C5b-9-mediated lysis.  Whether  sialic  acid leads 
to a net increase or decrease in lysis depends on the mode 
of complement activation  (classic  or  alternative  pathway) 
and  the  magnitude  of sialic  acid  inhibition  of activation 
versus enhancement of lysis. Consequently, microorganisms 
must evolve more than one mechanism to evade comple- 
ment attack efficiently. 
The structural features of sialic  acid required for inhibi- 
tion  of the  activation pathways  and  enhancement  of the 
membrane attack pathway show some interesting similari- 
ties.  Specifically, both pathways require  the  presence of a 
carboxylic acid on carbon 1 (31).  The exocyclic side chain 
consisting of carbons 8 and 9 is important in both factor H 
and C5b6 binding, although the requirements differ. Bind- 
ing ofsialic acid to factor H  requires the presence of carbon 
9  (31).  Binding  to  C5b6  is  enhanced  by the  presence  of 
carbons 8 and 9 of the exocyclic side chain; however, it is 
not an absolute requirement, and removal of only carbon 9 
has no effect on activity. The roles of the  glucose residue 
and  the  N-acetyl  group,  which  enhance  C5b6  binding, 
have not been investigated in the case of C3b degradation. 
The reason for these similarities is not known, but may be 
due to the fact that factor H  and C6 both share short con- 
sensus repeat (SCR)  protein modules. Factor H  consists of 
20 SCP,  s in linear array, and the SCR that is the probable 
anion-binding site has been identified (32). 
In addition  to the  SCP, modules, the terminal comple- 
ment  proteins  share  several  structural  domains  that  are 
found in other proteins such as the thrombospondin type 1 
motif (TS1),  the  low  density  lipoprotein  receptor  motif, 
the epidermal growth factor motif, and the factor I module 
(33).  C6  has three  and  C7  has two  TS1  repeat  domains. 
One  C6  thrombospondin motif shows close homology to 
human thrombospondin;  the  other two TS1  sequences in 
C6  and  both  of the  C7  TS1  domains  are  less  conserved 
(34).  TS1  domains are present in  a number of molecules, 
including thrombospondin, antistasin (an inhibitor of coag- 
ulation and metastasis), the malarial coat protein from sev- 
eral  plasmodia  species,  and  the  complement  protein 
properdin  (35,  36).  This sequence of amino acids binds to 
negatively charged molecules such as heparin, heparan sul- 
fate  proteoglycan,  sulfatides,  and  cholesterol  sulfate  (36). 
C5b6  binds  to  polyanions  such  as  heparin  and  sulfatides 
(Marshall, P.M., and M.B. Whitlow, unpublished observa- 
tions),  and  C6  binds  to  heparin-Sepharose  columns  (37). 
TS1  domains  contain  grouped  positive  charges  making 
them likely candidates to bind to anions such as sialic acid, 
but the precise binding site or sites for sialic  acid on C5b6 
remain to be elucidated. 
We propose the following mechanism for the interaction 
of the terminal complement proteins with glycophorin and 
gangliosides.  C5  and C6 do not have affinity for sialylated 
molecules. C5 is cleaved by the classic or alternative path- 
way C5  convertase and subsequently binds to C6 to form 
C5b6. This complex binds to the sialic acid residues of gly- 
cophorin  or gangliosides via ionic  forces. As  C6  contains 
one highly conserved TS1 domain, we postulate that this is 
the site of interaction between anions and C5b6.  Binding 
of C7 to C5b6 disrupts the ionic interaction between TS1 
and the membrane, and additionally leads to the exposure 
of hydrophobic residues on C5,  C6,  and C7.  C7  has two 
domains of grouped anionic  amino acids,  the low density 
lipoprotein domain,  and  the  epidermal growth factor do- 
main (38).  In our model, one of these domains binds to the 
TS1  domain of C6, and disrupts C5b6-membrane protein 
interaction. In addition, binding of C7 also induces the ex- 
posure ofhydrophobic domains on C5b, C6, and C7, lead- 
ing to membrane insertion (4,  10,  39).  Our model is novel 
as it emphasizes the importance of the ionic interaction be- 
tween C5b6 and membranes, and postulates that the addi- 
tion of C7 to the C5b6 complex not only leads to the ex- 
posure of hydrophobic domains, but also disrupts the ionic 
binding of C5b6 to membrane anions. This model predicts 
that  if the  C5b6-membrane  anion  binding  were  strong 
enough, C5b-7 formation would be inhibited.  Interestingly, 
this  question  was  addressed by Silversmith  and  Nelestuen 
(12).  They  examined  membrane binding  of the  terminal 
complement  proteins  on  vesicles  made  from  phosphati- 
dylglycerol, phosphatidylcholine, phosphatidylserine, phos- 
phatidylinositol,  and  phosphatidic  acid.  They  found  that 
vesicles  made  from  the  most  anionic  lipid,  phosphatidic 
acid, bound more C5b6 than vesicles made from the other 
lipids.  However,  this  membrane-bound  C5b6  could  not 
interact with C7  to form a C5b-7  complex. These results 
are consistent with our prediction that high affinity binding 
between membrane molecules and C5b6 will  inhibit C5b-7 
formation. 
When  gangliosides  or  glycophorin  are  present  in  the 
fluid  phase,  they  bind  to  C5b6,  and  compete  with  the 
membrane for C5b6 uptake. Thus our data do not contra- 
dict  previous  studies  showing  that  glycophorin  added  to 
the fluid phase inhibits complement deposition on erythro- 
cytes (40). 
The  requirement  for multivalency for  oligosaccharide- 
protein interaction,  as seen in Fig.  7,  has been previously 
described in selectins  (41).  The mechanism is not known, 
but has been postulated to be either due to summation of a 
large number of weak interactions,  or a specific secondary 
structure of the oligosaccharide residue that must be recog- 
nized (41), 
The observation that GTlb incorporated into the mem- 
brane increases lysis (Fig.  6) raises  the possibility that some 
of the gangliosides  used in the inhibition experiments (Fig. 5) 
incorporated  into  the  erythrocyte  membrane.  However, 
during the competition experiments, the gangliosides were 
in  contact  with  the  cells  for  much  shorter  times  and  at 
lower temperatures  (40 min at 30~  compared with  120 
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ments. As the amount of  lipid uptake increases as a function 
of time  and temperature,  any ganglioside incorporation in 
the  competition  experiments  will  be  minimized.  In addi- 
tion, the concentrations ofganglioside used in the incorpo- 
ration  experiments  were  significantly  higher  than  in  the 
competition  experiments.  Thus  any effect of incorporated 
gangliosides  in  these  experiments  should be  negligible,  al- 
though the true concentration of ganglioside that inhibited 
lysis by 50% (ICs0)  of the gangliosides may be slightly lower 
than the values shown. 
These studies clearly show the importance of ionic inter- 
actions in the process of membrane  attack by the terminal 
complement proteins.  In addition, the present findings pro- 
vide a strategy for the design of soluble and membrane in- 
hibitors  of the terminal  complement proteins.  Akami et al. 
(42), and Dong and Tomlinson (unpublished  observations) 
have shown that recombinant CD59 is more effective as an 
inhibitor of C5b-9 when it lacks the asparagine-linked  oli- 
gosaccharide which contains sialic  acid (42, 43). We would 
predict that any recombinant inhibitor of the membrane at- 
tack  complex should  lack  sialic  acid for maximal  activity. 
This  observation may prove to be important in the  design 
of genetically engineered organs to circumvent hyperacute 
xenograft rejection (20). 
This work also provides a strategy for the design of solu- 
ble complement inhibitors.  A  soluble form of complement 
receptor 1 (CR1, CD35) has been shown to decrease tissue 
damage in an animal model of myocardial infarction  (41). 
However,  soluble  inhibitors  of the  terminal  complement 
proteins have not been studied in vivo. Heparin is an effec- 
tive  in  vitro  inhibitor  of C5b-7  deposition,  but  heparin's 
anticoagulant  activity  limits  its  usefulness.  The  data  pre- 
sented in this study show that sialic  acid derivatives inhibit 
deposition  of the  terminal  complement  proteins.  Native 
gangliosides or glycophorin obviously cannot be used as in- 
hibitors  clinically;  however,  soluble  molecules  such  as  fe- 
tuin or synthetic fetuin derivatives might be possible C5b-9 
inhibitors.  In our studies fetuin effectively inhibited  C5b-9 
lysis  (not  shown).  In  addition,  the  presence  of sialylated 
molecules in the aqueous phase inhibition,  the presence of 
sialylated molecules in the aqueous phase inhibits the mem- 
brane attack pathway at the step of C5b-7 binding. This in- 
hibition should be additive with CD59 which inhibits lysis 
at the C8 and C9 stage of membrane attack. Recent studies 
have focused on the use oftransgenic pigs expressing CD59 
and DAF to avoid hyperacute xenograft rejection (44).  Thus 
an  optimal  strategy to  circumvent hyperacute gra~ rejection 
may involve tissue expression of DAF and CD59 as well as 
the presence of soluble sialic acid derivatives or other anions. 
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